Priscilla L Yang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1175877/publications.pdf

Version: 2024-02-01

48 papers	5,054 citations	236925 25 h-index	214800 47 g-index
54 all docs	54 docs citations	54 times ranked	8656 citing authors

#	Article	IF	Citations
1	Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer, 2009, 9, 28-39.	28.4	2,278
2	Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13825-13830.	7.1	353
3	Discovery of insect and human dengue virus host factors. Nature, 2009, 458, 1047-1050.	27.8	331
4	The Immunological Evolution of Catalysis. Science, 1996, 271, 1086-1091.	12.6	236
5	Immune effectors required for hepatitis B virus clearance. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 798-802.	7.1	206
6	Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nature Communications, 2019, 10, 3468.	12.8	124
7	c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3520-3525.	7.1	120
8	Peptide Inhibitors of Dengue-Virus Entry Target a Late-Stage Fusion Intermediate. PLoS Pathogens, 2010, 6, e1000851.	4.7	113
9	The Small Molecules AZD0530 and Dasatinib Inhibit Dengue Virus RNA Replication via Fyn Kinase. Journal of Virology, 2013, 87, 7367-7381.	3.4	105
10	Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharmaceutical Research, 2020, 37, 167.	3.5	102
11	Peptide Inhibitors of Flavivirus Entry Derived from the E Protein Stem. Journal of Virology, 2010, 84, 12549-12554.	3.4	85
12	Small-Molecule Inhibitors of Dengue-Virus Entry. PLoS Pathogens, 2012, 8, e1002627.	4.7	80
13	Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. Cell Chemical Biology, 2018, 25, 1006-1016.e8.	5.2	68
14	Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses. Antiviral Research, 2015, 124, 110-121.	4.1	66
15	Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay. Antiviral Research, 2008, 77, 232-236.	4.1	65
16	GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chemical Biology, 2016, 23, 443-452.	5.2	57
17	Anti-HCV drugs in the pipeline. Current Opinion in Virology, 2011, 1, 607-616.	5.4	56
18	Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (<s States of America, 2015, 112, E4354-63.	7.1	56

#	Article	IF	Citations
19	Mutational analysis of the affinity maturation of antibody 48G7. Journal of Molecular Biology, 1999, 294, 1191-1201.	4.2	51
20	The Bioactive Lipid 4-Hydroxyphenyl Retinamide Inhibits Flavivirus Replication. Antimicrobial Agents and Chemotherapy, 2015, 59, 85-95.	3.2	43
21	Identification of an Overabundant Cholesterol Precursor in Hepatitis B Virus Replicating Cells by Untargeted Lipid Metabolite Profiling. Journal of the American Chemical Society, 2009, 131, 5030-5031.	13.7	42
22	Lipid Metabolite Profiling Identifies Desmosterol Metabolism as a New Antiviral Target for Hepatitis C Virus. Journal of the American Chemical Society, 2012, 134, 6896-6899.	13.7	41
23	Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor. Journal of Virology, 2016, 90, 4494-4510.	3.4	29
24	Antiviral activity of N-(4-hydroxyphenyl) retinamide (4-HPR) against Zika virus. Antiviral Research, 2017, 147, 124-130.	4.1	29
25	Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo. ACS Infectious Diseases, 2019, 5, 460-472.	3.8	29
26	Mutagenesis of the DI/DIII Linker in Dengue Virus Envelope Protein Impairs Viral Particle Assembly. Journal of Virology, 2012, 86, 7072-7083.	3.4	28
27	Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein. ACS Infectious Diseases, 2018, 4, 1395-1406.	3.8	27
28	Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy. Molecular BioSystems, 2012, 8, 2523.	2.9	25
29	A Sensitive Yellow Fever Virus Entry Reporter Identifies Valosin-Containing Protein (VCP/p97) as an Essential Host Factor for Flavivirus Uncoating. MBio, 2020, 11, .	4.1	24
30	Hepatitis C Virus Selectively Alters the Intracellular Localization of Desmosterol. ACS Chemical Biology, 2016, 11, 1827-1833.	3.4	20
31	Lactimidomycin is a broad-spectrum inhibitor of dengue and other RNA viruses. Antiviral Research, 2016, 128, 57-62.	4.1	20
32	Fluorescent Visualization of Src by Using Dasatinibâ€BODIPY. ChemBioChem, 2014, 15, 1317-1324.	2.6	16
33	Structureâ€“Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent. ACS Medicinal Chemistry Letters, 2017, 8, 344-349.	2.8	16
34	How small-molecule inhibitors of dengue-virus infection interfere with viral membrane fusion. ELife, 2018, 7, .	6.0	16
35	Desmosterol Increases Lipid Bilayer Fluidity during Hepatitis C Virus Infection. ACS Infectious Diseases, 2016, 2, 852-862.	3.8	15
36	Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Research, 2017, 139, 171-179.	4.1	15

#	Article	IF	Citations
37	Identification of small molecule inhibitors targeting the Zika virus envelope protein. Antiviral Research, 2019, 164, 147-153.	4.1	14
38	Hepatitis C virus NS3-4A protease regulates the lipid environment for RNA replication by cleaving host enzyme 24-dehydrocholesterol reductase. Journal of Biological Chemistry, 2020, 295, 12426-12436.	3.4	10
39	Small-Molecule Inhibition of Viral Fusion Glycoproteins. Annual Review of Virology, 2021, 8, 459-489.	6.7	9
40	Chemoproteomic Profiling Identifies Changes in DNA-PK as Markers of Early Dengue Virus Infection. ACS Chemical Biology, 2012, 7, 2019-2026.	3.4	8
41	Current therapies under investigation for COVID-19: potential COVID-19 treatments. Canadian Journal of Physiology and Pharmacology, 2020, 98, 483-489.	1.4	6
42	Development of a genetic selection for catalytic antibodies. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1691-1694.	2.2	4
43	Antiviral Therapeutics. ACS Infectious Diseases, 2021, 7, 1297-1297.	3.8	4
44	A call to arms: Unifying the fight against resistance. Science Signaling, 2018, 11, .	3.6	3
45	A broad-spectrum antiviral molecule, QL47, selectively inhibits eukaryotic translation. Journal of Biological Chemistry, 2020, 295, 1694-1703.	3.4	3
46	Flaviviruses: Introduction to Dengue Viruses. , 2015, , 403-424.		2
47	Call for Papers: Antiviral Therapeutics. ACS Infectious Diseases, 2020, 6, 1527-1528.	3.8	1
48	A Sensitive Yellow Fever Virus Entry Reporter Identifies Valosin-Containing Protein (VCP/p97) as an Essential Host Factor for Flavivirus Uncoating. Proceedings (mdpi), 2020, 50, 147.	0.2	0